贝伐珠单抗联合XELOX化疗对结直肠癌疗效、血清CRP水平及生存时间的影响  

The Effect of Bevacizumab with XELOX Chemotherapy on Efficacy,Serum CRP Level and Survival Time of Patients with Colorectal Cancer

作　　者：梁振雄 王若天 符敏[1] 李炳[1] LIANG Zhenxiong;WANG Ruotian;FU Min(Qionghai People's Hospital,Qionghai 571400)

机构地区：[1]海南省琼海市人民医院

出　　处：《实用癌症杂志》2020年第2期326-329,共4页The Practical Journal of Cancer

摘　　要：目的探讨贝伐珠单抗联合XELOX化疗对结直肠癌患者疗效、血清CRP水平及生存时间的影响。方法选取60例结直肠癌患者,将患者随机分成试验组和对照组,每组30例。对照组采用XELOX化疗的方式。试验组采用贝伐珠单抗联合XELOX化疗。观察两组患者的疗效、血清CRP水平及生存时间情况。结果对照组的治疗有效率为36.67%,试验组患者治疗的总有效率为66.67%,试验组明显高于对照组(P<0.05),两组数据差异显著,有统计学意义。治疗前试验组和对照组的血清CRP水平无显著差异(P>0.05),治疗后试验组血清CRP水平明显低于对照组(P<0.05),数据差异有统计学意义。试验组患者的平均无进展生存时间和平均总生存期明显高于对照组(P<0.05),两组数据存在明显差异,具有统计学意义。结论贝伐珠单抗联合XELOX化疗能够有效提高结直肠癌患者的治疗效果,降低血清CRP水平,提高生存时间。Objective To explore the effect of bevacizumab with XELOX chemotherapy on efficacy,serum CRP level and survival time of patients with colorectal cancer.Methods 60 patients with colorectal cancer were randomly divided into the observation group and the control group,30 patients in each group.The control group was treated with XELOX chemotherapy;The observation group was treated with bevacizumab with XELOX chemotherapy.The efficacy,serum CRP level and survival time of the 2 groups were observed.Results Effective rate of treatment of the control group was 36.67%,and those of the observation group was 66.67%,the data of the observation group was significantly higher than that of the control group(P<0.05).There was no significant difference in serum CRP level between the observation group and the control group before treatment(P>0.05),and After treatment,serum CRP level in the observation group was significantly lower than that of the control group(P<0.05).Mean progression-free survival time and mean overall survival of the observation group were significantly higher than those of the control group(P<0.05).Conclusion Bevacizumab with XELOX chemotherapy can effectively improve the therapeutic effect of patients with colorectal cancer,which can reduce serum CRP level,and improve the survival time.

关 键 词：贝伐珠单抗 XELOX化疗 结直肠癌 血清CRP水平 生存时间 

分 类 号：R735.37[医药卫生—肿瘤]